United Therapeutics Corporation
UTHR
$535.29
-$0.83-0.16%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.16% | 0.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.16% | 0.11% | |||
| Cost of Revenue | 2.48% | 15.18% | |||
| Gross Profit | -1.69% | -1.74% | |||
| SG&A Expenses | 5.50% | -14.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.97% | -5.51% | |||
| Operating Income | -8.68% | 6.80% | |||
| Income Before Tax | 1.37% | 7.25% | |||
| Income Tax Expenses | -19.74% | 0.40% | |||
| Earnings from Continuing Operations | 7.56% | 9.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.56% | 9.43% | |||
| EBIT | -8.68% | 6.80% | |||
| EBITDA | -8.00% | 6.64% | |||
| EPS Basic | 8.80% | 12.68% | |||
| Normalized Basic EPS | -6.95% | 8.11% | |||
| EPS Diluted | 7.57% | 11.70% | |||
| Normalized Diluted EPS | -8.02% | 7.22% | |||
| Average Basic Shares Outstanding | -1.14% | -2.88% | |||
| Average Diluted Shares Outstanding | 0.00% | -2.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||